|
23,3 Mio. $ ATM Finanzierung
"Axsome Therapeutics, Inc. a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that today it raised approximately $23.3 million through the sale of 2,881,066 shares under its existing at-the-market (ATM) facility with Leerink Partners LLC."
axsometherapeuticsinc.gcs-web.com/...ews_date_value[min]=2019
AXS-12 Phase II Studie beginnt
seekingalpha.com/news/...d-stage-study-axsminus-12-narcolepsy
Axsome meldet Zahlen für 2018
"At December 31, 2018, Axsome had $14.0 million of cash. Including proceeds from the recently completed at-the-market equity financings and new growth capital term loan, Axsome’s pro forma cash balance was $52.6 million [...]
Axsome anticipates that its current cash, including proceeds from the January 2019 equity financings and March 2019 term loan, will be sufficient to fund its anticipated operations, based on its current operating plans, into at least the fourth quarter of 2021."
axsometherapeuticsinc.gcs-web.com/...ews_date_value[min]=2019
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 145 | Axsome Therapeutics | Mr. Gantzer | Vassago | 13.02.23 16:27 | |
2 | Axsome Therapeutics, Inc. (AXSM) | Chalifmann3 | Chalifmann3 | 25.04.21 00:07 |